Inpellis registers $20 million of common stock for initial public sale

Bookrunner Alexander Capital assists; deal finances drug development

By Devika Patel

Knoxville, Tenn., Nov. 12 – Inpellis, Inc. will price its initial public offering of common stock, according to an S-1 filed Thursday with the Securities and Exchange Commission. The company has registered up to $20 million of stock for the deal, which will be conducted on a best-efforts basis.

Alexander Capital, LP is the bookrunner.

Proceeds will be used for drug development, clinical trials, manufacturing clinical supplies, working capital and other general corporate purposes.

The Haddonfield, N.J., pharmaceutical company intends to list its common stock on the Nasdaq stock exchange under the symbol “INPL.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.